This press release may not be distributed directly or indirectly in Canada, Australia or Japan. This press release is not offering material and is for information purposes only. Innate pharma launches...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces revenue of...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today holds an R&D...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, today announced the...

Approval of issuance of 600,000 shares reserved to Novo Nordisk A/S as contemplated by the agreement on NKG2A checkpoint inhibitor acquisition by Innate Pharma Innate Pharma (Euronext Paris...

Innate Pharma will update investors and analysts on its pipeline and strategy The Company will present the clinical development plan of IPH2201 NKG2A checkpoint inhibitor, expected to start Phase II...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drugs for cancer and inflammatory diseases, today announces that the Data...

Innate Pharma (Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AGM”) on March 27, 2014, at 11:00 am in its headquarters, 117 avenue de Luminy, F-13009...

Successful €20.3 m private placement subscribed entirely by US-based specialist investors Stable cash burn Acquisition in February 2014 of anti-NKG2A, a Phase II-ready first-in-class checkpoint...

Novo Nordisk to reinforce its equity stake in Innate Pharma Marseille, France and Bagsværd, Denmark, 5 February 2014 Anti-NKG2A is a first-in-class therapeutic mAb that is Phase II ready NKG2A is a NK...